




The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 7.9% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 101% points below the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	82,380	Assets	151,436
Cost of Goods Sold	12,125	Liabilities	180,635
Intangible Assets	19,304	Expenses	90,454
Liabilities, Current	35,984	Revenues	59,215
Liabilities, Non-Current	132,878	Stockholders Equity	-29,199
Other Assets	49,208	Net Income	-33,226
Other Compr. Net Income	610	Comprehensive Net Income	-32,921
Other Expenses	15,229	BaseVar	242,168
Other Liabilities	11,773	ECR before LimitedLiability	-58%
Other Net Income	-1,987	Economic Capital Ratio	137%
Other Revenues	59,215		
Property and Equipment	544		
Research and Development	32,917		
Selling, General and Administrative Expense	30,183		